Trial Profile
Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabergoline (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Therapeutic Use
- 02 Apr 2007 New trial record.